Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patenting Human Embryonic Stem Cells in the EU

This article was originally published in SRA

Executive Summary

As is common with many new technologies, there are challenges involved in attempting to patent new developments in the field of biotechnology and, in particular, in stem cell technology. Not least, there are ethical and moral questions surrounding the artificial creation of life or cloning, and concerning human dignity and the right to life. There is also debate over balancing the destruction of embryos against the need to develop potential therapeutic agents. Such questions have, unsurprisingly, fed through into the realms of stem cell patenting, since patenting goes directly to the heart of commercialising technology.

Advertisement
Advertisement
UsernamePublicRestriction

Register

PS114022

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel